Sorafenib

BNF:
8.1.5
Status:
Red
Decision Date:
None
 

Comments

RED1,2,3: NICE TA474: Sorafenib for treating advanced hepatocellular carcinoma. (Decision date - Oct 2017)

RED 1,2,3: NICE TA535 - lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine. (Decision date - September 2018) NHS England drug. To be used in line with NHS England commissioning intentions

RED: SSC2588: maintenance for adults with FLT3-internal tandem duplication (FLT3-ITD) acute myeloid leukaemia (AML) undergoing allogeneic haematopoietic stem cell transplantation (allo-HSCT) as per NHSE commissioning intentions. (Decision date - January 2024)

 

 

Red Drug Classifications

  • 1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
  • 2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
  • 3: Requiring long term on-going monitoring of toxicity by a specialist (either because of difficulty in recognising side effects or high cost of investigations to identify toxicity)

search again